2023

NATICK, Mass. and RENO, NV – October 28, 2025 Pillar Biosciences, Inc., and Hamilton Company today announced the validation and release of their first automated NGS library preparation method under their NGS Application Development and Co-Marketing Agreement, for use on Hamilton Microlab® STARTM  liquid handling systems. Pillar’s research-use-only (RUO) oncoReveal® Essential MPN, a rapid 3-gene […]

NATICK, Mass. – October 23, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2025 Association for Molecular Pathology (AMP) Annual Meeting in Boston, MA. The company and scientific collaborators will collectively present eight studies and host three corporate workshops, showcasing their latest advancements in rapid Next-Generation Sequencing (NGS)

At ESMO 2025, Illumina teams up with Pillar Biosciences to showcase their powerful combination of NGS tests

September 4, 2025 – Pillar Biosciences, Inc., a leading provider of kitted next-generation sequencing (NGS) panels, and regulatory automation provider Platomics are collaborating to streamline compliance for next-generation sequencing (NGS) tests under the EU’s In Vitro Diagnostic Regulation (IVDR).    Now that IVDR has come into force, clinical laboratories must provide extensive regulatory documentation. Labs are

May 27, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received $34.5M in funding, including a strategic investment from Illumina, and structured financing from Soleus Capital and investments from existing investors. Proceeds from this financing will be leveraged to advance Pillar’s commercial activities including headcount and infrastructure to support

April 3, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received nationwide Medicare coverage by the Centers for Medicare & Medicaid Services (CMS) for oncoReveal® CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. oncoReveal® CDx is a NGS based IVD kit that uses Pillar’s proprietary SLIMamp (Stem-Loop

Collaboration aims to accelerate automation of rapid NGS testing February 18, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has entered into a strategic NGS automation application development agreement and co-marketing partnership with Hamilton Company. As part of this agreement, Hamilton will develop automation scripts and supporting technical and commercial literature for selected,

In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine™ and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted solutions. We’ve made substantial advancements and improved access to precision oncology solutions globally.  Here is a summary of select key achievements in 2024:  FDA Approval of oncoReveal® CDx In April, Pillar

Agreement aims to enhance Pillar’s PiVat® bioinformatics platform with downstream reporting capabilities. NATICK, Mass – January 7, 2025 – Pillar Biosciences, Inc. has entered into a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) for its proprietary OncoKB™ precision medicine knowledgebase.  OncoKB™ is the first somatic human variant database to receive FDA

Originally posted on Genomeweb Premium by Andrew P. Han September 12, 2024 NEW YORK – Memorial Sloan Kettering Cancer Center (MSK) is in the process of implementing a new rapid sequencing-based cancer panel to complement ongoing comprehensive genomic profiling (CGP).  The assay, branded as MSK-React, is based on a new panel from Pillar Biosciences, recently launched as